Radnet acquires AI imaging specialist Gleamer
Listed US-based radiology firm RadNet has acquired Gleamer, a Paris-based developer of medical imaging artificial intelligence, in a transaction valued at up to €230m. This all-cash deal represents a significant expansion for RadNet’s digital health subsidiary, DeepHealth, which now claims the position of the largest provider of radiology clinical AI solutions globally. For operators and clinical leaders, the integration of…
Alcon broadens Vision Care Portfolio with $1.5bn Acquisition of STAAR Surgical
Swiss-American pharmaceutical and medical device company Alcon has struck a definitive agreement to purchase STAAR Surgical in a deal which values the phakic IOL specialist at roughly $1.5 billion, but the shareholder vote on the takeover offer has been delayed until November 6.
Novo Nordisk acquiring Akero Therapeutics for $5.2bn
Denmark-based global pharma company Novo Nordisk is to acquire clinical stage company Akero Therapeutics for up to $5.2bn, filling a critical comorbidity gap within Novo Nordisk’s core therapeutic landscape. The deal adds potential first-in-class MASH (Metabolic Dysfunction-Associated Steatohepatitis, a severe form of fatty liver disease) therapy. This is Novo Nordisk’s largest R&D-focused acquisition to date, strategically aligning with its core…
Novo Nordisk trims 11% of workforce to refocus on diabetes and obesity core
Danish multinational pharmaceutical company Novo Nordisk’s September restructuring marks its largest organisational reset in decades. The Denmark-based group is in the process of eliminating around 9,000 of 78,400 positions (c. 5,000 in Denmark) as it seeks to simplify decision-making, free up capital and defend leadership in the increasingly crowded GLP-1 diabetes-and-obesity arena. With headcount having risen 73 % since 2020, new…
Genmab broadens late-stage portfolio with $8bn Merus acquisition
Copenhagen-based antibody therapeutics company Genmab has agreed to acquire Merus in a deal valuing the Dutch–U.S. oncology company at approximately $8bn. The move brings late-stage bispecific antibody petosemtamab into Genmab’s pipeline. Petosemtamab is in two Phase 3 trials for head and neck cancer, carries two FDA Breakthrough Therapy Designations, and could launch as early as 2027. According to Alcon’s management,…
Eugin expands Brazilian footprint with acquisition of Clínica Fertilidade e Vida
Spain-based Eugin Group, a global leader in reproductive medicine backed by Buenavista Equity Partners, has expanded its Latin American presence through the acquisition of Brazil’s Clínica Fertilidade e Vida. Eugin now operates over 30 centres across Europe (including Portugal, Italy, Sweden, Denmark, and Latvia) with a growing presence in Latin America. Clínica Fertilidade e Vida is a prominent reproductive medicine…
Spanish competition agency vetoes “competition threatening” radiopharma deal
Spain’s competition agency (CNMC) has prohibited Curium Pharma Holding Spain (Curium), a global leader in nuclear medicine, from acquiring Institut de Radiofarmacia Aplicada de Barcelona (IRAB). It said on Monday, October 6 that the merger poses an obstacle to effective competition in the markets for PET radiopharmaceuticals which are used in cancer detection tests, and contract manufacturing services to third…
IHH given green light on Fortis bid after seven-year regulatory delay
India’s Securities and Exchange Board (SEBI) has removed a seven-year regulatory overhang by allowing Malaysia-based IHH Healthcare Berhad to resume its long-awaited mandatory tender offers for Fortis Healthcare Ltd. and Fortis Malar Hospitals Ltd. The clearance, granted on October 1, enables IHH’s subsidiary Northern TK Venture Pte. Ltd. to acquire up to 26% in each company, potentially lifting its Fortis stake beyond the…
Roche Expands Metabolic Portfolio with US$3.5bn acquisition of 89bio
Swiss multinational pharma and diagnostics giant Roche has signed a definitive agreement to acquire California-based biotech group 89bio in a deal worth up to US$3.5bn, planning to expand in cardiovascular, renal and metabolic diseases while diversifying beyond oncology and immunology. Roche will pay US$2.4bn upfront, and up to US$3.5bn if certain milestones are hit tied to commercial success / annual sales targets.…
Fresenius Medical Care acquires kidney specialist Interwell Health
The world’s leading provider of products and services for people with chronic kidney failure, Fresenius Medical Care, has finalised its full acquisition of all non-physician stakes in the U.S.-based kidney care and support group Interwell Health (IWH) for €312m. The transaction strengthens Fresenius’ position as the undisputed leader in renal value-based care, uniquely combining nephrologist networks, clinic infrastructure, and proprietary health…